IL2 and melanoma: Combination regimens of IL-2, interferon-α (IFN-α), and cisplatin-based combination chemotherapies, while showing high overall response rates with some durable remissions, failed to significantly improve survival rates for patients with advanced melanoma and were subsequently abandoned [3].